MA56215A - Traitement topique du vitiligo par un inhibiteur de jak - Google Patents

Traitement topique du vitiligo par un inhibiteur de jak

Info

Publication number
MA56215A
MA56215A MA056215A MA56215A MA56215A MA 56215 A MA56215 A MA 56215A MA 056215 A MA056215 A MA 056215A MA 56215 A MA56215 A MA 56215A MA 56215 A MA56215 A MA 56215A
Authority
MA
Morocco
Prior art keywords
vitiligo
topical treatment
jak inhibitor
jak
inhibitor
Prior art date
Application number
MA056215A
Other languages
English (en)
French (fr)
Inventor
Kathleen Butler
Michael Howell
Fiona Kuo
Jim Lee
Kang Sun
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73651112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA56215A publication Critical patent/MA56215A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056215A 2019-06-10 2020-06-10 Traitement topique du vitiligo par un inhibiteur de jak MA56215A (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962859584P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US201962859495P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962894564P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894496P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894514P 2019-08-30 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US202062967879P 2020-01-30 2020-01-30

Publications (1)

Publication Number Publication Date
MA56215A true MA56215A (fr) 2022-04-20

Family

ID=73651112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056215A MA56215A (fr) 2019-06-10 2020-06-10 Traitement topique du vitiligo par un inhibiteur de jak

Country Status (10)

Country Link
US (4) US11602536B2 (cg-RX-API-DMAC10.html)
EP (1) EP3982971A4 (cg-RX-API-DMAC10.html)
JP (2) JP7532511B2 (cg-RX-API-DMAC10.html)
AU (2) AU2020290995B2 (cg-RX-API-DMAC10.html)
CA (1) CA3150975A1 (cg-RX-API-DMAC10.html)
IL (1) IL290637A (cg-RX-API-DMAC10.html)
MA (1) MA56215A (cg-RX-API-DMAC10.html)
TW (1) TW202112377A (cg-RX-API-DMAC10.html)
UA (1) UA130944C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020252012A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) 2018-08-10 2024-11-28 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
US20230364095A1 (en) * 2020-09-16 2023-11-16 Incyte Corporation Topical treatment of vitiligo
CN117279915A (zh) * 2021-02-18 2023-12-22 阿克拉瑞斯治疗股份有限公司 Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法
JP2024509383A (ja) * 2021-02-18 2024-03-01 アクラリス セラピューティクス，インコーポレイテッド アトピー性皮膚炎及びその他の皮膚状態の治療のためのｊａｋ１／３阻害剤の局所製剤及びその使用方法
EP4389114A4 (en) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd LOCAL TOPICAL FORMULATION CONTAINING A JAK INHIBITOR OR A SALT THEREOF OR A CRYSTALLINE FORM THEREOF, PREPARATION METHOD THEREOF AND CORRESPONDING APPLICATION
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP2019534304A (ja) 2016-11-10 2019-11-28 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性疾患の治療のための化合物及びその医薬組成物
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor

Also Published As

Publication number Publication date
CA3150975A1 (en) 2020-12-17
AU2020290995A1 (en) 2022-04-07
US20200405627A1 (en) 2020-12-31
US20220409622A1 (en) 2022-12-29
US11590138B2 (en) 2023-02-28
UA130944C2 (uk) 2026-06-24
US12233067B2 (en) 2025-02-25
TW202112377A (zh) 2021-04-01
AU2026200410A1 (en) 2026-02-12
JP2022545568A (ja) 2022-10-27
US20230355628A1 (en) 2023-11-09
AU2020290995B2 (en) 2025-12-11
JP2024105436A (ja) 2024-08-06
EP3982971A4 (en) 2023-08-16
WO2020252012A1 (en) 2020-12-17
IL290637A (en) 2022-04-01
EP3982971A1 (en) 2022-04-20
JP7532511B2 (ja) 2024-08-13
US20200383986A1 (en) 2020-12-10
US11602536B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
IL290637A (en) Topical treatment of vitiligo by jak inhibitor
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
EP4125884A4 (en) COMBINATIONS OF EIF4A INHIBITORS
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
DK3932919T3 (da) Jak-inhibitorforbindelse og anvendelse deraf
EP4495113A4 (en) KIF18A INHIBITOR
EP4434979A4 (en) KIF18A INHIBITOR
MA54622A (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
IL287904A (en) Combination treatment of arthritic disease
EP3937964A4 (en) TREATMENT OF ONCOGENE-DRIVEN CANCERS
MA52627A (fr) Traitement du cancer
EP4003299A4 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
EP3737383A4 (en) SYNERGISTIC CANCER TREATMENT
IL308335A (en) Combination therapies
EP4168398A4 (en) TYK-2 INHIBITOR
EP3962524A4 (en) CANCER TREATMENT
IL285020A (en) Topical phosphoinositide 3-kinase inhibitors
JP1778652S (ja) マッサージ器
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
IL285910A (en) Use of vibegron to treat overactive bladder
IL325421A (en) Combinational treatment
EP4319748A4 (en) TREATMENT OF CANCER WITH KDM4 INHIBITORS
EP3833378A4 (en) TREATMENT OF WARTS
EP4255426A4 (en) Y-BOX BINDING PROTEIN 1 INHIBITORS
MA56179A (fr) Traitement de synucléinopathies